Researchers found that a new activator called L687 induces cancer cells to accept delivery of antisense oligonucleotide (ASO) drugs. These drugs can treat cancer by blocking the transfer of messages from genes that encourage cancer growth. Previous methods to deliver ASOs into cells had only limited success. This research will help accelerate the development and delivery of novel ASO cancer therapies.
from Women's Health News -- ScienceDaily https://ift.tt/j2DN3Rh
0 comments:
Post a Comment